Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Rosiglitazone/pharmacology"'
Autor:
Jürg Hafner, Bao Khanh Trang, Catherine Moret, Mitchell P. Levesque, Helene Moser, Thanh Nhan Nguyen, Liliane Michalik, Christine Goepfert, Pedro Romero, Christine Pich, Patrick Meylan, Camilla Jandus, Romain Loyon, Beatris Mastelic-Gavillet
Publikováno v:
Cancer Research, Vol. 78, No 22 (2018) pp. 6447-6461
In addition to improving insulin sensitivity in type 2 diabetes, the thiazolidinedione family of compounds and the pharmacologic activation of their best-characterized target PPARγ have been proposed as a therapeutic option for cancer treatment. In
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f395a3c4d3390288cf5b5300fe9c4190
https://doi.org/10.5167/uzh-158449
https://doi.org/10.5167/uzh-158449
Autor:
Henning Beck-Nielsen, Kim Brøsen, Jeppe Gram, Niklas Rye Jørgensen, Morten Frost, Mette-Marie Hougaard Christensen, Tore Bjerregaard Stage
Publikováno v:
Stage, T B, Christensen, M-M H, Jørgensen, N R, Beck-Nielsen, H, Brøsen, K, Gram, J & Frost, M 2018, ' Effects of metformin, rosiglitazone and insulin on bone metabolism in patients with type 2 diabetes ', Bone, vol. 112, pp. 35-41 . https://doi.org/10.1016/j.bone.2018.04.004
BACKGROUND: Fracture risk is increased in individuals with type 2 diabetes (T2D). The pathophysiological mechanisms accentuating fracture risk in T2D are convoluted, incorporating factors such as hyperglycaemia, insulinopenia, and antidiabetic drugs.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0b5e526d85739b5b5a7d7d0ae4581eb0
https://curis.ku.dk/ws/files/222320195/1_s2.0_S8756328218301509_main.pdf
https://curis.ku.dk/ws/files/222320195/1_s2.0_S8756328218301509_main.pdf